Table 4.
Baseline pre-treatment variables associated with 5-year mortality, univariate cox regression
| Variable | 5-yr mortality rate, (%) | Hazard ratio (95%CI) | P value |
| Age (yr) | 1.02 (1.01; 1.04) | < 0.0001 | |
| Gender: male (n = 537) | 42.7 | 1.08 (0.83; 1.42) | 0.58 |
| Female (n = 170) | 42.3 | ||
| Comorbidity | |||
| Yes (n = 299) | 45.1 | 1.08 (0.86; 1.37) | 0.49 |
| No (n = 409) | 40.6 | ||
| Diabetes mellitus | |||
| Yes (n = 196) | 38.8 | 0.83 (0.63; 1.08) | 0.17 |
| No (n = 512) | 44 | ||
| NAFLD | |||
| Yes (n = 81) | 35.9 | 1.16 (0.81; 1.69) | 0.41 |
| No (n = 627) | 56.9 | ||
| ECOG 0-2 | |||
| Yes (n = 637) | 37.9 | 0.19 (0.14; 0.26) | 0.0001 |
| No (n = 71) | 84.5 | ||
| BCLC 0-A | |||
| Yes (n = 335) | 26 | 0.29 (0.23; 0.38) | 0.0001 |
| No (n = 373) | 57.4 | ||
| Cirrhosis | |||
| Yes (n = 639) | 42.9 | ||
| No (n = 69) | 39.1 | 0.86 (0.58; 1.28) | 0.45 |
| Child Pugh | |||
| A (n = 352) | 34.5 | - | |
| B (n = 238) | 41.6 | 1.38 (1.06; 1.83) | 0.019 |
| C (n = 118) | 68.6 | 3.23 (2.41; 4.34) | 0.0001 |
| Clinically significant portal hypertension | |||
| Yes (n = 484) | 40.2 | 1.22 (0.94; 1.57) | 0.13 |
| No (n = 224) | 43.7 | ||
| AFP > 1000 ng/mL | |||
| Yes (n = 106) | 64.1 | 3.09 (2.31; 4.15) | 0.0001 |
| No (n = 569) | 39.5 | ||
| Tumor vascular invasion | |||
| Yes (n = 74) | 77 | 4.74 (3.48; 6.44) | 0.0001 |
| No (n = 634) | 38.5 | ||
| Extrahepatic tumor disease | |||
| Yes (n = 48) | 70.8 | 3.29 (2.25; 4.81) | 0.0001 |
| No (n = 660) | 40.5 |
Normal Values: Alpha-fetoprotein 0.6-4.4 ng/mL. AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; ECOG: Eastern cooperative oncology group; HCC: Hepatocellular carcinoma; LT: Liver transplantation; WL: Waiting list; NAFLD: Non-alcoholic fatty liver disease.